PKPH / Retrieve Medical Holdings Inc - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-53855 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2022 o TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTIC

16.1 Letter from Friedman LLP to the Securities and Exchange Commission dated January 20, 2023

Exhibit 16.1 January 20, 2023 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by Peak Pharmaceuticals, Inc. under Item 4.01 of its Form 8-K dated January 20, 2023. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Peak Pharmaceuticals, I

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2023 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-53855 26-1973257 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 o TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 o TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS

Promissory Note dated July 22, 2021 with John Walters Nick, Jr. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.14 PROMISSORY NOTE Principal Amount: $7,500.00 July 22, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of John Walters Nick, Jr., located at 881 Robin Lane, Sebastian, FL 32958, or its

Promissory Note dated June 14, 2021 with Neil Reithinger (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)

Exhibit 10.7 PROMISSORY NOTE Principal Amount: $5,000.00 June 14, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Neil Reithinger, an individual, with a mailing address at 14201 N. Hayden Road,

Promissory Note dated September 28, 2021 with Neil Reithinger (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.20 PROMISSORY NOTE Principal Amount: $30,000.00 September 28, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Neil Reithinger, an individual, with a mailing address at 14201 N. Hayde

Promissory Note dated August 4, 2021 with Justin Schreiber (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.17 PROMISSORY NOTE Principal Amount: $35,000.00 August 4, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of JOJ Holdings, LLC, a limited liability company, with a place of business at

Promissory Note dated July 26, 2021 with Stefan Galluppi (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.16 PROMISSORY NOTE Principal Amount: $17,500.00 July 26, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Stefan Galluppi, located at 121 15th Street, Huntington Beach, CA 92648, or i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 o TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 o TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2020 o TRANSITION REPORT PURSUANT

10-Q 1 pkph123120-10q.htm PEAK PHARMACEUTICALS, INC. 12/31/2020 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transiti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2019 o TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 o TRANSITION REPORT PURSUANT TO S

10-Q 1 pkph063020-10q.htm PEAK PHARMACEUTICALS, INC. 06/30/2020 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 o TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

10-K 1 pkph093018-10k.htm PEAK PHARMACEUTICALS, INC. 09/30/2018 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Peri

Promissory Note dated July 22, 2021 with Gary Goodman (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.15 PROMISSORY NOTE Principal Amount: $17,500.00 July 22, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Gary & Adrienne Goodman, located at 14 Dorado Beach East, Dorado, Puerto Rico

Promissory Note dated June 30, 2021 with Utopia Capital, LLC (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)

Exhibit 10.9 PROMISSORY NOTE Principal Amount: $35,000.00 June 30, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Utopia Capital, LLC, a New Jersey limited liability company, with an address a

Promissory Note dated July 6, 2021 with Happy David Walters (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.12 PROMISSORY NOTE Principal Amount: $35,000.00 July 6, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Happy David Walters, an individual, residing at 21 The Enclave, Dorado, PR 006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 o TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2021 o TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTIC

Promissory Note dated July 6, 2021 with Church & Keeler, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.10 PROMISSORY NOTE Principal Amount: $35,000.00 July 6, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Church & Keeler, Inc., a Florida Corporation, 224 Bahama Lane, Palm Beach, FL

Promissory Note dated July 9, 2021 with Carriage House Capital, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.13 PROMISSORY NOTE Principal Amount: $17,500.00 July 9, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Carriage House Capital Inc., located at 35 Crest Loop, Staten Island, NY 10312

Promissory Note dated August 6, 2021 with Alexander Lim (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.18 PROMISSORY NOTE Principal Amount: $2,500.00 August 6, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Alexander Alim, an individual, with an address at P.O. Box 9513, Rancho Santa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS, IN

Promissory Note dated June 16, 2021 with Scott Lauer (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)

Exhibit 10.8 PROMISSORY NOTE Principal Amount: $2,500.00 June 16, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-l, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Scott Lauer, an individual, residing at 6540 E. Calle Del Media, Scottsdale, AZ

Promissory Note dated August 12, 2021 with Aliunde Limited (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.19 PROMISSORY NOTE Principal Amount: $17,500.00 August 12, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Aliunde Limited, a UK entity, located at Barnhouse Farm, Barnhouse Lane, Br

Promissory Note dated July 6, 2021 with Draper, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)

Exhibit 10.11 PROMISSORY NOTE Principal Amount: $17,500.00 July 6, 2021 FOR VALUE RECEIVED, Peak Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Nevada, having as its address at 14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 86260 (the “Borrower”), hereby promises to pay to the order of Draper, Inc., located at 35 Crest Loop, Staten Island, NY 10312, or its succes

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 o TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS

- PEAK PHARMACEUTICALS, INC. FORM 15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 333-156480 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified

PKPH / Peak Pharmaceuticals, Inc. PEAK PHARMACEUTICALS, INC. NT 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 005-87668 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on For

Convertible Promissory Note dated March 30, 2017 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on March 31, 2016.)

Exhibit 10.2 THIS CONVERTIBLE PROMISSORY NOTE (THE “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS PROMISSORY NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM

PKPH / Peak Pharmaceuticals, Inc. PEAK PHARMACEUTICALS, INC. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS,

Convertible Promissory Note dated March 21, 2017 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on March 31, 2016.)

Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (THE “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS PROMISSORY NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM

Convertible Promissory Note dated January 10, 2018 with Mediapark Investments Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)

EXHIBIT 10.3 THIS PROMISSORY NOTE (THE “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS PROMISSORY NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION

First Amendment to Convertible Promissory Note dated May 7, 2018 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)

EXHIBIT 10.6 FIRST AMENDMENT TO CONVERTIBLE PROMISSORY NOTE This First Amendment to Convertible Note Promissory Note (the “Note Amendment”) dated this 7th day of May, 2018 amends that certain Convertible Promissory Note (the “Note'') dated March 21, 2017 between Peak Pharmaceuticals, Inc. (the “Company') and Trius Holdings Limited (the “Holder”). WHEREAS: A. Pursuant to beginning description of th

Convertible Promissory Note dated April 2, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)

EXHIBIT 10.4 THIS PROMISSORY NOTE (THE “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND THIS PROMISSORY NOTE, THE SECURITIES AND ANY INTEREST THEREIN MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION

PKPH / Peak Pharmaceuticals, Inc. PEAK PHARMACEUTICALS, INC. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS

First Amendment to Convertible Promissory Note dated May 7, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)

EXHIBIT 10.5 FIRST AMENDMENT TO CONVERTIBLE PROMISSORY NOTE This First Amendment to Convertible Note Promissory Note (the “Note Amendment”) dated this 7th day of May, 2018 amends that certain Convertible Promissory Note (the “Note'') dated March 21, 2017 between Peak Pharmaceuticals, Inc. (the “Company') and Trius Holdings Limited (the “Holder”). WHEREAS: A. Pursuant to beginning description of th

PKPH / Peak Pharmaceuticals, Inc. PEAK PHARMACEUTICALS, INC. NT 10-Q

Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 005-87668 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Repo

PKPH / Peak Pharmaceuticals, Inc. PEAK PHARMACEUTICALS, INC. 10-KQ (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: September 30, 2017 ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 005-87668 PEAK PHARMACE

PKPH / Peak Pharmaceuticals, Inc. PEAK PHARMACEUTICALS, INC. NT 10-K

Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 005-87668 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Rep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: September 30, 2016 ☐ TRANSITION REPORT PURS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: September 30, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 005-87668 PEAK PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 005-87668 PEAK PHARMACEUTICALS

Responsive Letter from EideBailly LLP (incorporated by reference to our Registration Statement on Form 8-K filed on July 18, 2016)

Exhibit 16.1 Exhibit 16.1 July 15, 2016 Securities and Exchange Commission 100 F Street Washington, DC 20549 Ladies and Gentlemen: On July 12, 2016, we resigned as the independent registered public accounting firm for Peak Pharmaceuticals, Inc. (the Company). We have read the Company?s disclosure set forth in Item 4.01, ?Changes in Registrant?s Certifying Accountant? of the Company?s Current Repor

Current Report

Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 12, 2016 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File

Peak Pharmaceuticals 0-Q

Form 12b-25 Late Filing Notice for 12/30 Form 10-Q (00023841).DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 005-87668 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20

Current Report

8-K 1 peakform8kdirectorresignatio.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 7, 2016 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdict

EX-17

EX-17 6 ex173yachinresignation.htm EXHIBIT 17.3 April 7, 2016 From: Guy Yachin To: Board of Directors, Peak Pharmaceuticals Cc: Neil Reithinger, Gary Joiner Dear Board of Directors, This letter is to inform you that I resign as a director of Peak Pharmaceuticals, effective immediately. My resignation is not the result of a disagreement with the Company on any matter relating to its operations, pol

April 7, 2016

EX 17.1 April 7, 2016 From: Soren Mogelsvang To: Board of Directors, Peak Pharmaceuticals Cc: Neil Reithinger, Gary Joiner Dear Board of Directors, This letter is to inform you that I resign as a director of Peak Pharmaceuticals, effective immediately. My resignation is not the result of a disagreement with the Company on any matter relating to its operations, policies or practices. Kind regards S

EX-17

EX 17.2

Current Report

Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 31, 2016 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Peak Pharmaceuticals FORM 12B-25

Form 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 12b-25 NOTIFICATION OF LATE FILING (Check one) Form 10-K Form 20-F Form 11-K X Form 10-Q Form N-SAR Form N-CSR For period ended: December 31, 2015 ( ) Transition Report on Form 10-K ( ) Transition Report on Form 20-F ( ) Transition Report on Form 11-K ( ) Transition Report on Form 10-Q ( ) Transition Report on

Current Report

Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 18, 2016 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2014 [] TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2014 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to PEAK PHARMACEUTICALS, INC. (Exact name of registrant as

Peak Pharmaceuticals 0-K

Form 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 12b-25 NOTIFICATION OF LATE FILING (Check one) X Form 10-K Form 20-F Form 11-K Form 10-Q Form N-SAR Form N-CSR For period ended: September 30, 2015 ( ) Transition Report on Form 10-K ( ) Transition Report on Form 20-F ( ) Transition Report on Form 11-K ( ) Transition Report on Form 10-Q ( ) Transition Report o

EX-10

Exhibit 16.1 AGREEMENT FOR TERMINATION OF LICENSE AGREEMENT THIS AGREEMENT FOR TERMINATION OF LICENSE AGREEMENT, is made and entered into this 12th day of October, 2015, to be effective as of October 1, 2015, by and between CANNA-PET, LLC, a Washington limited liability company (?LICENSOR?), and PEAK BIOPHARMA CORP., a Colorado corporation (?LICENSEE?). RECITALS Licensor is the owner of the brand

Other Events

Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 12, 2015 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission Fi

EX-16

EXHIBIT 16.1 EXHIBIT 16.1 MaloneBailey, LLP 9801 Westheimer, Suite 1100 Houston, Texas 77042 October 12, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K of Peak Pharmaceuticals, Inc. for the event that occurred on October 9, 2015, and we agree with the statements concerning our firm contained therein. Very t

Current Report

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 9, 2015 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number)

Peak Pharmaceuticals, Inc. Shifts Strategic Focus to Human Product Development

Form 99.1 Peak Pharmaceuticals, Inc. Shifts Strategic Focus to Human Product Development -Company terminates license agreement for animal health products BOULDER, CO, October 13, 2015 ? Peak Pharmaceuticals, Inc. (OTCQB: PKPH) (?Peak Pharma? or the ?Company?), a dedicated proponent of research, development, sales and marketing of safe, hemp-based health products, today announced the termination of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 005-87668 Peak Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 005-87668 Peak Pharmac

Financial Statements and Exhibits, Other Events

Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 17, 2015 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission F

For the three months ended December 31,

PKPH Press Release dated 2/17/2015 Peak Pharmaceuticals, Inc. Provides Business Update for the First Quarter of Fiscal 2015 -Company Reports First Revenues with 72.7% Gross Margin BOULDER, CO, February 17, 2015 – Peak Pharmaceuticals, Inc. (OTCQB: PKPH) (“Peak Pharma” or the “Company”), an emerging leader in the research, development, sales and marketing of safe, hemp-based, medicinal products and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 005-87668 Peak Phar

EX-10

Executive Employment Agreement EMPLOYMENT SERVICES AGREEMENT This Employment Services Agreement (the “Agreement”) is entered into as of the 1st day of February, 2015, by and between Peak Pharmaceuticals, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

Form 8K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 30, 2015 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2014 [] TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2014 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to PEAK PHARMACEUTICALS, INC. (Exact name of registrant as

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 24, 2014 PEAK PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission F

Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)

Articles of Merger

Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)

AGREEMENT AND PLAN OF MERGER AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER, dated as of December 23, 2014, is by and between Cannabis Therapy Corp, a Nevada corporation ("Parent"), and Peak Pharmaceuticals, Inc, a Nevada corporation and a direct wholly-owned subsidiary of Parent (Parent and Peak Pharmaceuticals, Inc.

PKPH / Peak Pharmaceuticals, Inc. NT 10-K - -

NT 10-K 1 f12b2510ksept14.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 12b-25 NOTIFICATION OF LATE FILING (Check one) X Form 10-K Form 20-F Form 11-K Form 10-Q Form N-SAR Form N-CSR For period ended: September 30, 2014 ( ) Transition Report on Form 10-K ( ) Transition Report on Form 20-F ( ) Transition Report on Form 11-K ( ) Transition Report on Form 10-Q ( ) T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 005-87668 CANNABIS THER

EX-10.14

EXHIBIT 10.14

EX-10.13

EXHIBIT 10.13 SERVICES AGREEMENT THIS SERVICES AGREEMENT (“Agreement”) is made as of June 26, 2014, by and between Caerus Discovery, LLC, a Delaware limited liability company with its principal place of business located at 10650 Pyramid Place, Manassas, Virginia 20110 (“Caerus”), and Cannabis Therapy Corp, a Nevada corporation with its principal place of business located at 4450 Arapahoe Avenue, S

EX-21.1

EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Peak BioPharma Corp., a Colorado corporation

EX-10.12

EXHIBIT 10.12 Farm Lease And Service Agreement This Lease and Service Agreement (this "Lease") is made effective as of May 01, 2014, by and between Rocky Mountain Hemp Inc. and Ryan Loflin, ("Landlord"), and Peak BioPharma Corp ("Tenant"). The parties agree as follows: PREMISES. Landlord, in consideration of the lease payments provided in this Lease, leases to Tenant two (2) acres of certified org

Change in Shell Company Status

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 8, 2014 CANNABIS THERAPY CORP. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number) (I.R

EX-10.1

EX-10.1 2 ctcoex101.htm LICENSE AGREEMENT EXHIBIT 10.1 LICENSE AGREEMENT between CANNA-PET, LLC. and PEAK BIOPHARMA CORP. THIS LICENSING AGREEMENT (“Agreement”) is entered into as of July 29, 2014, by CANNA-PET, LLC, a Washington limited liability company, with its corporate address at 10115 Greenwood Avenue N. 191, Seattle, WA 98133 (“LICENSOR”), and PEAK BIOPHARMA CORP., a Colorado corporation,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 29, 2014 CANNABIS THERAPY CORP. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.

Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 22, 2014 CANNABIS THERAPY CORP. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S

CANNABIS THERAPY CORP. 2014 EQUITY INCENTIVE PLAN

EXHIBIT 10.1 CANNABIS THERAPY CORP. 2014 EQUITY INCENTIVE PLAN 1. PURPOSE. The Cannabis Therapy Corp. 2014 Equity Incentive Plan has two complementary purposes: (a) to attract and retain outstanding individuals to serve as officers, employees, directors, consultants and advisors to the Company and its Affiliates, and (b) to increase stockholder value. The Plan will provide participants incentives

EX-10.1

EXHIBIT 10.1 SERVICES AGREEMENT THIS AGREEMENT (this “Agreement”) is made as of May 15, 2014 (the “Effective Date”) by and between Axiom Group, a corporation organized under the laws of the State of Nevada (“Axiom”) and Cannabis Therapy Corp (OTCQB: CTCO) a corporation organized under the laws of the State of Nevada with a place of business at 4450 Arapahoe Avenue, Suite 100, Boulder, CO 80303 (“C

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 15, 2014 CANNABIS THERAPY CORP. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 005-87668 CANNABIS THE

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 30, 2014 CANNABIS THERAPY CORP. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number) (I.R

Other Events - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 24, 2014 CANNABIS THERAPY CORP. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number) (I.R

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 14, 2014 CANNABIS THERAPY CORP. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number) (I.R

Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)

EXHIBIT 2.1

Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)

EXHIBIT 2.2 AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER, dated as of March 14, 2014, is entered into by and between Frac Water Systems, Inc., a Nevada corporation (“FWSI”), and Cannabis Therapy Corp., a Nevada corporation (“CTC”). RECITALS A. CTC is a wholly-owned subsidiary of FWSI; B. The boards of directors of CTC and FWSI deem it advisable and in the best interests of their

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Other Events - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 10, 2014 FRAC WATER SYSTEMS, INC. (Exact name of registrant as specified in its charter) Nevada 005-87668 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 005-87668 FRAC WATE

- NT 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 005-87668 CUSIP Number: 35169E 102 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR ForPeriod Ended: December 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Transition Period Ended: N/A Read Instructions (on back page) Before Preparing Form.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2014 FRAC WATER SYSTEMS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 005-87668 26-1973257 (State or Other Jurisdiction of Incorporation) (Commission Fil

Termination of a Material Definitive Agreement, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2013 FRAC WATER SYSTEMS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 005-87668 26-1973257 (State or Other Jurisdiction of Incorporation) (Commission Fi

EX-14.1

EXHIBIT 14.1 FRAC WATER SYSTEMS, INC. CODE OF ETHICS FOR CHIEF EXECUTIVE OFFICER, CHIEF FINANCIAL OFFICER, CHIEF ACCOUNTING OFFICER OR CONTROLLER AND PERSONS PERFORMING SIMILAR FUNCTIONS General Philosophy The honesty, integrity and sound judgment of the Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer or Controller and persons performing similar functions (collectively t

EX-21.1

EXHIBIT 21.1 Subsidiaries of the Registrant None.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Fiscal Year Ended: September 30, 2013 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 005-87668 FRAC WATER SYSTEMS, INC. (Ex

Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2013 FRAC WATER SYSTEMS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 005-87668 26-1973257 (State or Other Jurisdiction of Incorporation) (Commission Fil

PKPH / Peak Pharmaceuticals, Inc. / SMITH NADINE C - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* FRAC WATER SYSTEMS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 35169E 102 (CUSIP Number) Nadine C. Smith 1266 1st Street, Suite 4 Sarasota, FL 34236 Phone: (941) 330-6404 With a copy to: Adam S. Gottbett

EX-10.1

EXHIBIT 10.1 JOINT VENTURE AGREEMENT THIS JOINT VENTURE AGREEMENT (the “Agreement”) is made as of the 10th day of October, 2013, by and between FRAC WATER SYSTEMS, INC., a company organized under the laws of the State of Nevada (“FWSI”), and PRODUCED WATER SOLUTIONS, INC., a company organized under the laws of the State of Colorado (“PWS”) (FWSI and PWS may hereinafter sometimes be referred to sin

EX-10.4

EXHIBIT 10.4 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of October 15, 2013, by and between FRAC WATER SYSTEMS, INC., a Nevada corporation (the “Company”), and ARNOLD TINTER (“Consultant,” and together with the Company, the “Parties”). RECITALS WHEREAS, the Company desires to engage Consultant to provide the Services (as defined below), and Consul

SHARE CANCELLATION AGREEMENT

EXHIBIT 10.8 SHARE CANCELLATION AGREEMENT SHARE CANCELLATION AGREEMENT, dated October 10, 2013 (this “Agreement”), by and between, Frac Water Systems, Inc., a Nevada corporation (the “Company”), and Fadi Zeidan (the “Cancelling Party”). BACKGROUND WHEREAS, the Company was formed to engage in the development, sales and marketing of online video stores (the “Legacy Business”); and WHEREAS, the Cance

Form of Registrant’s 10% Senior Convertible Promissory Note (incorporated by reference to our Registration Statement on Form 8-K filed on October 17, 2013)

EXHIBIT 4.1 For U.S. Investors: THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, (C) IN COMPLIANCE WITH RULE 1

FRAC WATER SYSTEMS, INC. 2013 EQUITY INCENTIVE PLAN

EXHIBIT 10.6 FRAC WATER SYSTEMS, INC. 2013 EQUITY INCENTIVE PLAN 1. PURPOSE. The Frac Water Systems, Inc. 2013 Equity Incentive Plan has two complementary purposes: (a) to attract and retain outstanding individuals to serve as officers, employees, directors, consultants and advisors to the Company and its Affiliates, and (b) to increase stockholder value. The Plan will provide participants incenti

EX-10.3

EXHIBIT 10.3 EMPLOYMENT SERVICES AGREEMENT This Employment Services Agreement (the “Agreement”) is entered into as of the 10th day of October, 2013, by and between Frac Water Systems, Inc., a Nevada corporation, with a business address of 1266 1st Street, Suite 4, Sarasota, FL 34236 (the “Company”), and Nadine C. Smith, an individual with an address at 1266 1st Street, Suite 4, Sarasota, FL 34236

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2013 FRAC WATER SYSTEMS, INC. (Exact name of registrant as specified in its charter) Nevada 333-156480 26-1973257 (State or other jurisdiction of incorporation) (Commissio

EX-10.2

EXHIBIT 10.2 SETTLEMENT AGREEMENT AND MUTUAL RELEASE This Settlement Agreement and Mutual Release Agreement (“Agreement”) made as of October 10, 2013 is by and among Produced Water Solutions, Inc., a Colorado corporation (“PWS”), Frac Water Systems, Inc., a Nevada corporation (“FWSI”), and Montrose Capital Limited (“Montrose”). R E C I T A L S WHEREAS, PWS and Montrose are parties to a June 13, 20

EX-10.7

EXHIBIT 10.7 SHARE CANCELLATION AGREEMENT SHARE CANCELLATION AGREEMENT, dated October 10, 2013 (this “Agreement”), by and between, Frac Water Solutions, Inc., a Nevada corporation (the “Company”), and Ufuk Turk (the “Cancelling Party”). BACKGROUND WHEREAS, the Company was formed to engage in the development, sales and marketing of online video stores (the “Legacy Business”); and WHEREAS, the Cance

EX-10.5

EXHIBIT 10.5 FRAC WATER SYSTEMS, INC. 1266 1st Street, Suite 4 Sarasota, FL 34236 , 2013 (Name and Address) Re: Frac Water Systems, Inc. Directorship Offer Dear : It is my pleasure to offer you a position to serve on the Board of Directors of Frac Water Systems, Inc., a Nevada corporation (“FWSI”) on the terms described herein: · You will be eligible to purchase shares of common stock of FWSI at a

Other Events - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 12, 2013 FRAC WATER SYSTEMS, INC. (Exact name of registrant as specified in its charter) Nevada 333-156480 26-1973257 (State or other jurisdiction of incorporation) (Commission File Numbe

Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)

EX-2.2 3 fracex22.htm AGREEMENT AND PLAN OF MERGER EXHIBIT 2.2 1 2 3

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 30, 2013 FRAC WATER SYSTEMS, INC. (Exact name of registrant as specified in its charter) Nevada 333-156480 26-1973257 (State or other jurisdiction of incorporation) (Commission File Number)

Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)

EXHIBIT 2.1 1 2 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 333-156480 SURF A MOVIE SOLUTIONS INC. (Exact name of registrant a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 333-156480 SURF A MOVIE SOLUTIONS INC. (Exact name of registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 333-156480 SURF A MOVIE SOLUTIONS INC. (Exact name of registra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2012 Commission File No. 000-53855 SURF A M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2012 Commission File No. 000-53855 SURF A MOVIE SOLUTIONS INC. (Exact name of registrant as specified in its charter) Nevada 26-1973257 (State or other jurisdiction of (I.R.S. Employer incorpor

Certificate of Change (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)

EXHIBIT 3.1.3

Certificate of Amendment to Articles of Incorporation (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)

EXHIBIT 3.1.2 1 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 333-156480 SURF A MOVIE SOLUTIONS INC. (Exact name of registrant a

SURF A MOVIE SOLUTIONS INC. A MINIMUM OF 400,000 AND A MAXIMUM OF 600,000 SHARES OF COMMON STOCK OFFERING PRICE $0.10 PER SHARE

PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-156480 SURF A MOVIE SOLUTIONS INC. A MINIMUM OF 400,000 AND A MAXIMUM OF 600,000 SHARES OF COMMON STOCK OFFERING PRICE $0.10 PER SHARE This prospectus relates to the offering by Surf A Movie Solutions Inc. (the ?Company? or the ?Registrant?) of a minimum of 400,000 (the ?Minimum Shares?) and a maximum of 600,000 (the ?Maximum Shares?

Surf a Movie Solutions Inc. 19744 Beach Blvd., Ste 149, Huntington Beach, CA 92648-2988 February 10, 2009

Surf a Movie Solutions Inc. 19744 Beach Blvd., Ste 149, Huntington Beach, CA 92648-2988 February 10, 2009 Mr. Matthew Spitzer, Attorney-Advisor Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Mail Stop 3561 Washington, DC 20549 Re: Surf a Movie Solutions Inc. Registration Statement on Form S-1 filed on December 29, 2008, and amended on January 26, 2009 and Febru

EX-10.3

Exhibit 10.3 To: Surf A Movie Solutions, Inc. FORMOF SURF A MOVIE SOLUTIONS, INC. INVESTMENT CONFIRMATION The undersigned, intending to be legally bound, hereby irrevocably subscribes for and agrees to purchase shares of the common stock of Surf A Movie Solutions, Inc., a Nevada corporation (the ?Company?), for an aggregate purchase price of $, or $0.10 per share. Simultaneous with the execution a

**************

February 5, 2009 VIA EDGAR AND OVERNIGHT MAIL Mr. Matthew Spitzer, Attorney-Advisor Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Mail Stop 3561 Washington, DC 20549 Re: Surf a Movie Solutions Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed on January 26, 2009 File No. 333-156480 (the ?Registration Statement?) Dear Mr. Spitzer: We are counsel

As filed with the Securities and Exchange Commission on February 5, 2009

As filed with the Securities and Exchange Commission on February 5, 2009 Registration No.

**************

January 26, 2009 VIA EDGAR AND OVERNIGHT MAIL Mr. Matthew Spitzer, Attorney-Advisor Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Mail Stop 3561 Washington, DC 20549 Re: Surf a Movie Solutions Inc. Registration Statement on Form S-1 Filed on December 29, 2008 File No. 333-156480 (the ?Registration Statement?) Dear Mr. Spitzer: We are counsel to Surf a Movie So

EX-10.3

Exhibit 10.3 To: Surf A Movie Solutions, Inc. FORMOF SURF A MOVIE SOLUTIONS, INC. INVESTMENT CONFIRMATION The undersigned, intending to be legally bound, hereby irrevocably subscribes for and agrees to purchase shares of the common stock of Surf A Movie Solutions, Inc., a Nevada corporation (the “Company”), for an aggregate purchase price of $, or $0.10 per share. Simultaneous with the execution a

As filed with the Securities and Exchange Commission on January 26, 2009

As filed with the Securities and Exchange Commission on January 26, 2009 Registration No.

Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)

BY-LAWS OF SURF A MOVIE SOLUTIONS INC (the “Corporation”) * * * * * * * * * * * ARTICLE I Offices The Corporation may have offices at such other places, both within and without the State of Nevada, as the Board of Directors may determine and designate from time to time or the business of the Corporation requires.

Specimen Common Stock Certificate (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)

INCORPORATED UNDER THE LAWS OF THE STATE OF NEVADA SURF A MOVIE SOLUTIONS INC. COMMON STOCK PAR VALUE $0.001 EACH THE CORPORATION WILL FURNISH WITHOUT CHARGE TO ANY SHAREHOLDER WHO SO REQUESTS THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OR SERIES THEREOF AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFER

Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)

EX-10.2

THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE "SUBSCRIPTION AGREEMENT") RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.

EX-10.1

THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE "SUBSCRIPTION AGREEMENT") RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.

EX-10.3

Exhibit 10.3 To: Surf A Movie Solutions, Inc. FORMOF SURF A MOVIE SOLUTIONS, INC. INVESTMENT CONFIRMATION The undersigned, intending to be legally bound, hereby irrevocably subscribes for and agrees to purchase shares of the common stock of Surf A Movie Solutions, Inc., a Nevada corporation (the “Company”), for an aggregate purchase price of $, or $0.10 per share. Simultaneous with the execution a

Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)

As filed with the Securities and Exchange Commission on December 29, 2008 Registration No.